169 related articles for article (PubMed ID: 21185825)
21. Contribution to safe anti-inflammatory therapy with indomethacin.
Bauerová K; Nosál'ová V; Mihalová D; Navarová J
Cent Eur J Public Health; 2004 Mar; 12 Suppl():S8-10. PubMed ID: 15141962
[TBL] [Abstract][Full Text] [Related]
22. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage.
Takeuchi K; Tanaka A; Kato S; Amagase K; Satoh H
Clin Chim Acta; 2010 Apr; 411(7-8):459-66. PubMed ID: 20074562
[TBL] [Abstract][Full Text] [Related]
23. Protective effects of proton pump inhibitors against indomethacin-induced lesions in the rat small intestine.
Pozzoli C; Menozzi A; Grandi D; Solenghi E; Ossiprandi MC; Zullian C; Bertini S; Cavestro GM; Coruzzi G
Naunyn Schmiedebergs Arch Pharmacol; 2007 Jan; 374(4):283-91. PubMed ID: 17151854
[TBL] [Abstract][Full Text] [Related]
24. Soluble Dietary Fibers Can Protect the Small Intestinal Mucosa Without Affecting the Anti-inflammatory Effect of Indomethacin in Adjuvant-Induced Arthritis Rats.
Satoh H; Matsumoto H; Hirakawa T; Wada N
Dig Dis Sci; 2016 Jan; 61(1):91-8. PubMed ID: 26423078
[TBL] [Abstract][Full Text] [Related]
25. [Experimental study of the impact of a single use of indometacine on the morphological structure of the mucous coat of the stomach and small intestine].
Vymiatina ZK; Ivanova LA; Krylova SG
Eksp Klin Gastroenterol; 2006; (3):32-6, 70. PubMed ID: 17203840
[TBL] [Abstract][Full Text] [Related]
26. NSAID-induced enteropathy: are the currently available selective COX-2 inhibitors all the same?
Fornai M; Antonioli L; Colucci R; Pellegrini C; Giustarini G; Testai L; Martelli A; Matarangasi A; Natale G; Calderone V; Tuccori M; Scarpignato C; Blandizzi C
J Pharmacol Exp Ther; 2014 Jan; 348(1):86-95. PubMed ID: 24135073
[TBL] [Abstract][Full Text] [Related]
27. Effect of ursodeoxycholic acid on the inflammatory activity of indomethacin-induced intestinal inflammation in rats.
Kullmann F; Gross V; Rüschoff J; Arndt H; Benda W; Winkler von Mohrenfels A; Schölmerich J
Z Gastroenterol; 1997 Mar; 35(3):171-8. PubMed ID: 9106980
[TBL] [Abstract][Full Text] [Related]
28. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent.
Watanabe T; Higuchi K; Kobata A; Nishio H; Tanigawa T; Shiba M; Tominaga K; Fujiwara Y; Oshitani N; Asahara T; Nomoto K; Takeuchi K; Arakawa T
Gut; 2008 Feb; 57(2):181-7. PubMed ID: 17639086
[TBL] [Abstract][Full Text] [Related]
29. Pathogenic importance of intestinal hypermotility in NSAID-induced small intestinal damage in rats.
Takeuchi K; Miyazawa T; Tanaka A; Kato S; Kunikata T
Digestion; 2002; 66(1):30-41. PubMed ID: 12379813
[TBL] [Abstract][Full Text] [Related]
30. Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats.
Yokota A; Taniguchi M; Takahira Y; Tanaka A; Takeuchi K
J Pharmacol Exp Ther; 2005 Jul; 314(1):302-9. PubMed ID: 15831440
[TBL] [Abstract][Full Text] [Related]
31. Indomethacin induces free radical-mediated changes in renal brush border membranes.
Basivireddy J; Jacob M; Balasubramanian KA
Arch Toxicol; 2005 Aug; 79(8):441-50. PubMed ID: 15889237
[TBL] [Abstract][Full Text] [Related]
32. Activation of phospholipase A2 is involved in indomethacin-induced damage in Caco-2 cells.
Sivalingam N; Basivireddy J; Pulimood AB; Balasubramanian KA; Jacob M
Toxicol In Vitro; 2009 Aug; 23(5):887-96. PubMed ID: 19470405
[TBL] [Abstract][Full Text] [Related]
33. HSP70 confers protection against indomethacin-induced lesions of the small intestine.
Asano T; Tanaka K; Yamakawa N; Adachi H; Sobue G; Goto H; Takeuchi K; Mizushima T
J Pharmacol Exp Ther; 2009 Aug; 330(2):458-67. PubMed ID: 19458285
[TBL] [Abstract][Full Text] [Related]
34. Adverse effects of nonsteroidal anti-inflammatory drugs on the small and large bowel.
Schneider AR; Benz C; Riemann JF
Endoscopy; 1999 Nov; 31(9):761-7. PubMed ID: 10604623
[TBL] [Abstract][Full Text] [Related]
35. The healing of NSAID-induced gastric lesion may be followed by small intestinal and cardiovascular side effects.
Filaretova LP; Bagaeva TR; Morozova OY; Zelena D
J Physiol Pharmacol; 2011 Dec; 62(6):619-25. PubMed ID: 22314564
[TBL] [Abstract][Full Text] [Related]
36. Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine.
Bertrand V; Guimbaud R; Tulliez M; Mauprivez C; Sogni P; Couturier D; Giroud JP; Chaussade S; Chauvelot-Moachon L
Br J Pharmacol; 1998 Aug; 124(7):1385-94. PubMed ID: 9723949
[TBL] [Abstract][Full Text] [Related]
37. Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats.
Konaka A; Nishijima M; Tanaka A; Kunikata T; Kato S; Takeuchi K
J Physiol Pharmacol; 1999 Mar; 50(1):25-38. PubMed ID: 10210152
[TBL] [Abstract][Full Text] [Related]
38. Skin disruption is associated with indomethacin-induced small intestinal injury in mice.
Yokoyama S; Hiramoto K; Koyama M; Ooi K
Exp Dermatol; 2014 Sep; 23(9):659-63. PubMed ID: 25041031
[TBL] [Abstract][Full Text] [Related]
39. Exacerbation of indomethacin-induced small intestinal injuries in Reg I-knockout mice.
Imaoka H; Ishihara S; Kazumori H; Kadowaki Y; Aziz MM; Rahman FB; Ose T; Fukuhara H; Takasawa S; Kinoshita Y
Am J Physiol Gastrointest Liver Physiol; 2010 Aug; 299(2):G311-9. PubMed ID: 20508157
[TBL] [Abstract][Full Text] [Related]
40. Dopamine-induced protection against indomethacin-evoked intestinal lesions in rats--role of anti-intestinal motility mediated by D2 receptors.
Miyazawa T; Matsumoto M; Kato S; Takeuchi K
Med Sci Monit; 2003 Feb; 9(2):BR71-7. PubMed ID: 12601282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
